ChiCTR-INR-16008616
尚未开始
/
/
/
2016-06-08
/
/
原發性鼻淚管阻塞
比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞 的手術療效
比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞 的手術療效
比較絲裂黴素C合併支架植入術與單純黏膜瓣保留鼻內鏡下淚囊鼻腔吻合術對原發性鼻淚管阻塞的手術療效.
随机平行对照
治疗新技术
Randomized
Single-blind
Research Grants Council
/
340
/
1990-01-01
1990-01-01
/
Adult >=18 years old and there is no maximum age limit; Primary acquired nasolacrimal duct obstruction (PANLDO) diagnosed by lacrimal irrigation and probing, confirmed intraoperatively after incision of lacrimal sac; Informed consent for operation, randomization and recording; Compliance to follow-up and treatment.;
登录查看Pregnancy, lactation (contraindication for topical mitomycin C); Known allergy to mitomycin, cocaine, adrenaline, steroid, silicone material; Contraindications of endonasal DCR or inability to undergo nasal endoscopy; Acute (<3 months) or non-bacterial dacryocystitis e.g. tuberculosis, fungal or parasitic; Ipsilateral canalicular disorder e.g. obstruction, canaliculitis, canaliculocele, diverticulum; Ipsilateral recurrent NLDO or any prior lacrimal intervention except punctoplasty; Ipsilateral facial paralysis despite apparent clinical recovery; Ipsilateral conditions affecting bony nasolacrimal outflow e.g. midfacial trauma/fracture42, osteoma, fibrous dysplasia and other skull-base disorders; Ipsilateral suspected or confirmed nasolacrimal or sinoorbital neoplasm 43; Ipsilateral severe ocular surface disorders e.g. ocular cicatrical pemphigoid, chemical burns, Steven Johnson Syndrome, Toxic Epidermal Necrolysis44; Conditions affecting mucosa of the nose or nasolacrimal system e.g. rhinosinusitis, Wegener’s granulomatosis, sarcoidosis45, radioactive iodide46, head & neck radiotherapy47, ipsilateral maxillectomy48, systemic chemotherapy (5-fluorouracil, docetaxel49); Ipsilateral topical antiglaucomatous or chemotherapy drops (e.g. timolol50, mitomycin C); Intraoperative false passage of Bowman probe or metal part of silicone stent; Dacryolith or intrasaccal mass.;
登录查看Research Grants Council
/
diabetes 埃诺格鲁肽 SLIMMER
医药笔记2025-06-22
遗传性血管性水肿 III期 BD项目
美柏资本2025-06-22
ADA GIPR PCSK9
信达生物2025-06-22
diabetes 埃诺格鲁肽 内分泌学
先为达生物2025-06-22
PDL1 三阴性乳腺癌 atezolizumab
BioArtMED2025-06-21
EGFR 结直肠癌 JMT101
石药集团2025-06-21
糖尿病 GLP-1/GIP
恒瑞医药2025-06-21
肥胖 Wegovy
一度医药2025-06-21